Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Account Payables (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Account Payables for 17 consecutive years, with -$4.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 281.82% to -$4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.4 million, a 129.79% decrease, with the full-year FY2025 number at -$1.4 million, down 129.79% from a year prior.
  • Change in Account Payables was -$4.2 million for Q4 2025 at Myriad Genetics, down from -$800000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $14.0 million in Q4 2021 to a low of -$12.9 million in Q3 2021.
  • A 5-year average of $278947.4 and a median of -$800000.0 in 2025 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 1266.67% in 2021, then plummeted 1166.67% in 2022.
  • Myriad Genetics' Change in Account Payables stood at $14.0 million in 2021, then plummeted by 117.14% to -$2.4 million in 2022, then tumbled by 145.83% to -$5.9 million in 2023, then soared by 81.36% to -$1.1 million in 2024, then tumbled by 281.82% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Change in Account Payables are -$4.2 million (Q4 2025), -$800000.0 (Q3 2025), and $3.6 million (Q2 2025).